-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $260

Benzinga·07/14/2026 11:05:58
語音播報
Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $253 to $260.